Cardinal Health's CALRAD Mark VI Dose Calibrator Receives FDA Clearance

CLEVELAND, Ohio (September 22, 2003) — Cardinal Health Inc. (NYSE: CAH), the leading provider of products and services supporting the health care industry, today announced it has obtained FDA 510(k) clearance for the Nuclear Associates CALRAD Mark VI Dose Calibrator, which will soon be available for immediate delivery.

Available through the company’s Radiation Management Services business, the CALRAD Mark VI offers what today’s health care professionals have been asking for – increased productivity, dose accuracy and reduced patient dose – so that they can spend more time focusing on what matters most — patient care.

“The Mark VI has features never before seen in nuclear medicine departments,” said Frank Talbot, manager of the Nuclear Medicine Product Line. “The device’s automated future dose calculations give users confidence that the correct activities will be drawn each and every time. A touch-screen interface combined with Microsoft® Windows XP® saves time, greatly increasing cost effectiveness not only for the health care provider but also the patient.”

Timesaving features of the CALRAD Mark VI include a touch-screen interface; Microsoft Windows XP embedded system; ±1% electrometer accuracy; built-in, menu-driven software for automated linearity, using the decay or sleeve method; geometry, accuracy, constancy, molybdenum breakthrough and system checks; quality assurance protocols for daily and quarterly checks; kit inventory control for remembering activity and volume in prepared kits and an extensive isotope library.

About Radiation Management Services

The Radiation Management Services business of Cardinal Health is the industry leader in providing solutions for maintaining a safe, regulatory-compliant facility in the medical imaging and therapy fields and the nuclear power industry. Radiation detection instruments and information management software under the famous Victoreen brand and QA accessories, supplies and phantoms under the Nuclear Associates brand are recognized worldwide. (www.cardinal.com/rms).

About Cardinal Health

Cardinal Health, Inc. (www.cardinal.com)is the leading provider of products and services supporting the health care industry. Cardinal Health companies develop, manufacture, package and market products for patient care; develop drug-delivery technologies; distribute pharmaceuticals, medical-surgical and continents and produces annual revenues of more than $47 billion. Cardinal Health is ranked #19 on the current Fortune 500 list and was named one of “The World’s Best” companies by Forbes magazine in 2003.

Except for historical information, all other information in this news release consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. The most significant of these uncertainties are described in Cardinal Health's Form 10-K, Form 8-K and Form 10-Q reports (including all amendments to those reports) and exhibits to those reports, and include (but are not limited to) the costs, difficulties, and uncertainties related to the integration of acquired businesses, the loss of one or more key customer or supplier relationships, changes in the distribution patterns or reimbursement rates for health-care products and/or services, the costs and other effects of governmental regulation and legal and administrative proceedings, and general economic and market conditions. Cardinal Health undertakes no obligation to update or revise any forward-looking statements.

> Return to News Page